The revelation of CCR5 antagonism as a synergistic approach to combine with radiotherapy to enhance anti-tumour effector T cell function is a compelling therapeutic concept and warrants further interrogation of the repurposing of the FDA-approved CCR5 antagonist Maraviroc for the treatment of OAC. The gene discussed is CCR5; the disease is neoplasm.